Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.

Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, Kohno S.

Hypertens Res. 2004 Dec;27(12):963-70.

2.
3.

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD.

Am J Kidney Dis. 2006 Jul;48(1):8-20. Review.

PMID:
16797382
4.
5.

ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials.

Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH.

Int J Clin Pract. 2009 Jun;63(6):880-8. doi: 10.1111/j.1742-1241.2009.02038.x. Review.

PMID:
19490198
6.

Angiotensin antagonists and fish oil for treating IgA nephropathy.

Coppo R, Amore A, Peruzzi L, Mancuso D, Camilla R.

Contrib Nephrol. 2007;157:27-36. Review.

PMID:
17495434
7.

Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.

Parvanova A, Chiurchiu C, Ruggenenti P, Remuzzi G.

Expert Opin Pharmacother. 2005 Sep;6(11):1931-42. Review.

PMID:
16144512
8.

Proteinuria: clinical signficance and basis for therapy.

Woo KT, Lau YK.

Singapore Med J. 2001 Aug;42(8):385-9. Review.

PMID:
11764058
9.
10.

Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis.

Cheng J, Zhang X, Tian J, Li Q, Chen J.

Int J Clin Pract. 2012 Oct;66(10):917-23. doi: 10.1111/j.1742-1241.2012.02970.x. Review.

PMID:
22994326
11.

Therapeutic approach of patients with IgA nephropathy.

Goumenos DS, Brown CB.

Ren Fail. 2004 Mar;26(2):171-7. Review.

PMID:
15287202
12.

[Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].

Pozzi C, Del Vecchio L, Locatelli F.

G Ital Nefrol. 2002 Sep-Oct;19(5):523-8. Review. Italian.

PMID:
12439840
13.

Treatment of IgA nephropathy.

Pozzi C.

J Nephrol. 2016 Feb;29(1):21-5. doi: 10.1007/s40620-015-0248-3. Epub 2015 Nov 17. Review.

PMID:
26577268
14.

[Therapeutic effects of RAS inhibitor in IgA nephropathy].

Kashihara N.

Nihon Jinzo Gakkai Shi. 2008;50(4):473-7. Review. Japanese. No abstract available.

PMID:
18546877
15.
16.

[IgA nephropathy. Significance of immunoglobulin A glycosylation in pathogenesis and clinical presentation].

Matousovic K, Konecný K, Mĕstecký J, Tomana M, Novák J.

Cas Lek Cesk. 2002 Nov 22;141(23):729-34. Review. Czech.

PMID:
12650029
17.

[Management of IgA nephropathy].

Amoroso L, De Sanctis L, Cappelli P, Di Vito R, Sirolli V, Bonomini M.

G Ital Nefrol. 2011 Nov-Dec;28(6):622-32. Review. Italian.

PMID:
22167613
18.

Renal failure and ACE inhibition: how much is too much?

Gross ML, Adamczak M, Ritz E.

Z Kardiol. 2005 Feb;94(2):81-6. Review.

PMID:
15674737
19.

Slowing nephropathy progression: focus on proteinuria reduction.

Bakris GL.

Clin J Am Soc Nephrol. 2008 Jan;3 Suppl 1:S3-10. doi: 10.2215/CJN.03250807. Review.

20.

[IgA nephropathy].

Alamartine E.

Rev Prat. 2003 Nov 30;53(18):2023-6. Review. French.

PMID:
15008216

Supplemental Content

Support Center